SEA4 Antibody

What is SSEA-4 and what is its significance in cancer research?

SSEA-4 is a glycosphingolipid (ganglioside) that has gained significant attention in cancer research due to its overexpression in various solid tumors. It functions as a transcriptional activator that binds with high affinity to the T-cell enhancer motif 5'-AACAAAG-3' . SSEA-4 is particularly important in cancer research because it identifies heterogeneous, invasive subpopulations of tumor cells and is associated with tumor progression through its influence on cellular adhesion to the extracellular matrix .

Unlike many other cancer markers, SSEA-4 expression is exclusively found in cells derived from solid tumors but not from leukemic blasts, making it a potentially valuable marker for solid tumor characterization . The expression of SSEA-4 on the cell surface is associated with the loss of cell-cell interactions and the gain of a migratory phenotype, suggesting its crucial role in cancer invasion and metastasis .

What are the most reliable antibodies for SSEA-4 detection?

Several well-characterized monoclonal antibodies are available for SSEA-4 detection, each with distinct properties and applications. The mouse monoclonal anti-SSEA-4 antibody (clone CL5665, ab243739) has been cited in multiple publications and is suitable for immunohistochemistry with paraffin-embedded sections (IHC-P) and immunocytochemistry/immunofluorescence (ICC/IF) . This antibody has been validated for reactivity with mouse, rat, and human samples .

Research has also highlighted the IPS-K-4A2B8 monoclonal antibody, which demonstrated superior separation capacity compared to the commercially available MC-813-70 antibody . Glycan array analysis revealed that IPS-K-4A2B8 binds to SSEA-4 with approximately 50-fold higher affinity (30,000 RFU) compared to MC-813-70 (600 RFU) . Specificity testing through blocking experiments confirmed that preincubation with SSEA-4 molecule significantly inhibited (87.94%) the binding of IPS-K-4A2B8 to NT-2 cells, while preincubation with structurally related SSEA-3 or GM1b did not affect binding .

What applications are SSEA-4 antibodies suitable for?

SSEA-4 antibodies have demonstrated utility across multiple experimental applications. The CL5665 clone (ab243739) is specifically validated for immunohistochemistry with paraffin-embedded sections (IHC-P) and immunocytochemistry/immunofluorescence (ICC/IF) . Research applications include:

• Flow cytometry for identification and isolation of SSEA-4+ cell populations from heterogeneous tumor samples or cell lines

• Immunohistochemical analysis of formalin-fixed, paraffin-embedded tissues, as demonstrated with mouse forebrain tissue at a 1/1000 dilution

• Immunofluorescence studies of fixed, permeabilized cells, as shown with PFA-fixed, Triton X-100 permeabilized SH-SY5Y human neuroblastoma cells at 10 μg/ml concentration

• Identification of tumor cells undergoing spontaneous epithelial-to-mesenchymal transition (EMT)

• Monitoring tumor heterogeneity and studying subpopulations with different tumorigenic potential

When selecting an application, researchers should consider the specific epitope recognized by the antibody and its validated species reactivity.

How should I optimize immunohistochemistry protocols for SSEA-4 detection?

Optimization of immunohistochemistry protocols for SSEA-4 detection requires attention to several critical factors:

• Sample preparation: Formalin fixation and paraffin embedding have been successfully used with SSEA-4 antibodies. Ensure consistent fixation time to preserve antigenic sites while maintaining tissue morphology .

• Antigen retrieval: SSEA-4 is a glycosphingolipid, and its detection may require specialized antigen retrieval methods. Heat-induced epitope retrieval in citrate buffer (pH 6.0) is often effective.

• Antibody concentration: Titration is essential. For the CL5665 clone (ab243739), a 1/1000 dilution has been successfully used for IHC-P on mouse forebrain tissue .

• Detection system: Use a detection system appropriate for the host species of the primary antibody. For mouse monoclonal antibodies like CL5665, polymer-based detection systems can reduce background staining from endogenous mouse immunoglobulins in mouse tissues.

• Controls: Include positive controls (tissues known to express SSEA-4, such as embryonic stem cells), negative controls (tissues known not to express SSEA-4, such as leukemic cell lines), and technical controls (primary antibody omission) .

• Signal localization: SSEA-4 expression may be heterogeneous within tumors, with enrichment often observed in the tumor periphery rather than the tumor core, as demonstrated in xenograft studies .

What cell types typically express SSEA-4?

SSEA-4 expression demonstrates a distinctive pattern across different cell types:

• Solid tumor cell lines: SSEA-4 is expressed in subpopulations of many solid tumor cell lines, including prostate cancer (DU145, PC3), colorectal cancer (HCT-116), and breast cancer (MCF-7) cell lines .

• Leukemic cell lines: Notably, SSEA-4 expression was not detected in leukemic cell lines, suggesting a specific association with solid tumors .

• Embryonic stem cells: As its name suggests, Stage-specific embryonic antigen-4 is expressed in embryonic stem cells and is associated with pluripotency.

• Cancer stem cells: SSEA-4+ cells from cancer cell lines show enrichment for pluripotent embryonic stem cell markers including Tra-1-60, Tra-1-81, and SSEA-3, suggesting an association with stem-like properties .

• Mesenchymal-like cancer cells: SSEA-4+ cancer cells typically display fibroblast-like morphology with limited cell-cell contacts, in contrast to SSEA-4- cells which exhibit cobblestone-like epithelial morphology .

• Migratory cancer cells: SSEA-4 is enriched in cells that escape from adhesive colonies spontaneously and form invadopodia-like migratory structures .

How can I isolate and characterize SSEA-4+ cells from heterogeneous tumor samples?

Isolation and characterization of SSEA-4+ cells from heterogeneous tumor samples involve several methodological approaches:

• Flow cytometry-based isolation: Fluorescence-activated cell sorting (FACS) with high-affinity SSEA-4 antibodies has been successfully used to separate SSEA-4+ and SSEA-4- populations. For optimal separation, use antibodies with superior discrimination capability like IPS-K-4A2B8 .

• Multi-parameter analysis: Combine SSEA-4 staining with other markers such as E-cadherin, CD44, and other epithelial or stem cell markers to better characterize the subpopulations. Flow cytometric analysis of xenografts has revealed that the majority of SSEA-4+ cells are negative for CD44 and E-cadherin .

• Morphological characterization: After isolation, observe the distinct morphological characteristics of SSEA-4+ cells, which typically form spindle-shaped, fibroblast-like colonies with limited cell-cell contacts, in contrast to the cobblestone-like epithelial morphology of SSEA-4- cells .

• Gene expression analysis: Perform quantitative real-time PCR or microarray analysis to compare gene expression profiles between SSEA-4+ and SSEA-4- populations. SSEA-4+ cells typically show decreased expression of epithelial markers (CDH1/E-cadherin, ESRP1, GRHL2, CLDN7) and increased expression of mesenchymal markers (CDH2/N-cadherin) and SSEA-4 synthesizing enzyme ST3GAL2 .

• Functional characterization: Assess the tumorigenic potential through xenotransplantation experiments, which have demonstrated that SSEA-4+ cells display higher tumorigenic ability compared to SSEA-4- or CD44+ cells .

What is the relationship between SSEA-4 expression and pluripotency markers?

SSEA-4 expression shows a significant correlation with pluripotency markers, suggesting its role in identifying cells with stem-like properties:

• Co-expression with embryonic stem cell markers: Flow cytometric analysis reveals that SSEA-4+ cells isolated from DU145 and HCT-116 cancer cell lines are highly enriched for pluripotent embryonic stem cell markers Tra-1-60 and Tra-1-81 compared to SSEA-4- cells or unfractionated cells . Similarly, SSEA-4+ MCF-7 cells are highly enriched for the pluripotent embryonic stem cell marker SSEA-3 .

• Cell line-dependent associations: The relationship between SSEA-4 and other pluripotency markers can vary by cell line. For example, while SSEA-4+ DU145, HCT-116, and MCF-7 cells show enrichment for embryonic markers, PC3 cells do not demonstrate this association because the parental PC3 cells do not express these markers .

• Dynamic expression patterns: SSEA-4 expression is not static but rather dynamic, with SSEA-4- cells spontaneously generating SSEA-4+ cells and vice versa. This plasticity suggests that SSEA-4 expression may reflect a cellular state rather than a fixed cell identity .

• Functional implications: The enrichment of pluripotency markers in SSEA-4+ cells correlates with their enhanced tumorigenic potential, as demonstrated in xenotransplantation experiments where SSEA-4+ cells showed superior tumor formation compared to SSEA-4- cells, particularly when small numbers of cells were transplanted .

How does SSEA-4 expression correlate with epithelial-to-mesenchymal transition?

SSEA-4 expression strongly correlates with epithelial-to-mesenchymal transition (EMT), suggesting its role as a marker for cells undergoing this process:

• Morphological changes: SSEA-4+ cells display fibroblast-like morphology with limited cell-cell contacts, characteristic of cells that have undergone EMT, while SSEA-4- cells maintain epithelial cobblestone morphology .

• Downregulation of epithelial markers: Gene expression analysis reveals that SSEA-4+ cells show decreased expression of epithelial cell markers including CDH1 (E-cadherin), ESRP1 (epithelial-specific splicing factor 1), GRHL2 (grainyhead transcription factor 2), and CLDN7 (tight junction protein) . This molecular signature is consistent with loss of epithelial characteristics during EMT.

• Upregulation of mesenchymal markers: SSEA-4+ cells demonstrate increased expression of mesenchymal markers such as CDH2 (N-cadherin) compared to SSEA-4- cells . Additionally, the SSEA-4 synthesizing enzyme ST3GAL2 is upregulated in SSEA-4+ cells .

• Migration and invasion properties: SSEA-4+ cells spontaneously escape from adhesive colonies and form invadopodia-like migratory structures, in which SSEA-4 is colocalized with motility markers like cortactin and active signaling molecules (pPI3K, pAkt, pSrc) . These features are characteristic of cells that have undergone EMT and acquired invasive capabilities.

• Primary tumor validation: Analysis of SSEA-4+ cells from primary prostate tumors (not just cell lines) confirmed the downregulation of epithelial markers and upregulation of EMT markers , validating the relevance of this correlation in clinical samples.

What are appropriate positive and negative controls for SSEA-4 antibody experiments?

Establishing appropriate controls is critical for reliable SSEA-4 antibody experiments:

Positive Controls:

• Cell lines with known SSEA-4 expression: DU145, HCT-116, PC3, and MCF-7 cell lines have been characterized for SSEA-4 expression and can serve as positive controls . NT-2 cells have also been used in antibody validation studies .

• Embryonic stem cells: As SSEA-4, is a stage-specific embryonic antigen, embryonic stem cells naturally express SSEA-4 and can serve as biological positive controls.

• Tissues with known expression: Mouse forebrain tissue has been validated for SSEA-4 expression with the CL5665 antibody clone at a 1/1000 dilution .

Negative Controls:

• Leukemic cell lines: These have been demonstrated to lack SSEA-4 expression despite expressing the synthesizing enzyme ST3GAL2, making them suitable negative controls .

• Antibody controls: Include isotype controls matched to the primary antibody class and concentration to assess non-specific binding.

• Blocking controls: Preincubation of the antibody with purified SSEA-4 molecule should abolish staining, while preincubation with structurally related molecules like SSEA-3 or GM1b should not affect binding . This approach verifies specificity.

• Knockdown controls: Cells with ST3GAL2 knockdown (the enzyme involved in SSEA-4 synthesis) show reduced SSEA-4 expression and can serve as negative controls .

Technical Controls:

• Primary antibody omission: To assess background from the detection system.

• Concentration gradients: Titration of antibody to determine optimal signal-to-noise ratio.

• Multiple detection methods: Verification of results using different techniques (flow cytometry, IHC, IF) increases confidence in the findings.

How stable is SSEA-4 expression in cultured cells?

SSEA-4 expression demonstrates interesting dynamics in cultured cells, with important implications for experimental design:

• Spontaneous interconversion: Research has shown that SSEA-4- cells spontaneously generate SSEA-4+ cells and vice versa in culture. When sorted SSEA-4- cells are cultured, they eventually regenerate a SSEA-4+ population comparable to that of the parental cell line .

• Equilibrium restoration: Following sorting and separation, both SSEA-4+ and SSEA-4- populations tend to return to an equilibrium distribution similar to the parental cell line over time. This suggests that SSEA-4 expression is regulated by dynamic processes rather than representing fixed subpopulations .

• In vivo plasticity: Even in xenograft tumors, SSEA-4 expression shows plasticity. Analysis of tumors generated from SSEA-4- cells reveals the spontaneous acquisition of SSEA-4+ phenotype and vice versa . This explains why there is only a 2-3 fold difference in tumor initiation between SSEA-4+ and SSEA-4- populations.

• Culture conditions influence: The proportion of SSEA-4+ cells can be influenced by culture conditions that affect cell adhesion and EMT status. Since SSEA-4 expression correlates with EMT markers, conditions that promote or inhibit EMT may alter the SSEA-4+ population size.

• Implications for experiments: This plasticity has important implications for experimental design. Short-term experiments are necessary to study distinct properties of freshly isolated SSEA-4+ and SSEA-4- cells before significant interconversion occurs. For long-term studies, researchers should account for this dynamic expression pattern and consider periodic resorting or analysis of SSEA-4 expression over time.

What molecular mechanisms regulate SSEA-4 synthesis and expression in cancer cells?

The regulation of SSEA-4 synthesis and expression in cancer cells involves several molecular mechanisms:

How can I validate the specificity of a new SSEA-4 antibody?

Validating the specificity of a new SSEA-4 antibody requires a comprehensive approach:

• Glycan array analysis: This powerful method can confirm binding specificity to the SSEA-4 glycan structure. For example, both IPS-K-4A2B8 and MC-813-70 antibodies were tested on a glycan array comprising 611 glycan targets, and both bound exclusively to the SSEA-4 glycan (Neu5Aca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0), demonstrating their specificity .

• Blocking experiments: Preincubate the antibody with purified SSEA-4 molecule before cell staining. Specific antibodies will show significantly reduced binding, as demonstrated with IPS-K-4A2B8, which showed 87.94% inhibition after preincubation with SSEA-4 . Similar experiments with structurally related molecules (SSEA-3, GM1b) should not significantly affect binding .

• Comparative analysis with established antibodies: Compare staining patterns with well-characterized antibodies. IPS-K-4A2B8 was compared with MC-813-70, revealing superior separation capacity despite both antibodies binding specifically to SSEA-4 .

• Knockdown studies: Perform shRNA knockdown of ST3GAL2, the enzyme responsible for SSEA-4 synthesis. A specific antibody should show reduced staining in knockdown cells, as demonstrated in DU145 cells where ST3GAL2 knockdown reduced SSEA-4+ cells from 21.5% to 4% .

• Cross-reactivity testing: Test the antibody on cell lines known to be positive (solid tumor lines) and negative (leukemic cell lines) for SSEA-4 expression .

• Multiple detection methods: Validate binding using different techniques (flow cytometry, IHC, IF) to ensure consistent results across platforms.

• Epitope mapping: Determine the specific region of SSEA-4 recognized by the antibody. The immunogen information (e.g., synthetic peptide within Human SOX4 aa 300-350 for ab243739) is crucial for understanding potential cross-reactivity .

What technical challenges exist in analyzing SSEA-4 expression in primary tumor samples?

Analyzing SSEA-4 expression in primary tumor samples presents several technical challenges:

How can I design functional experiments to assess the role of SSEA-4 in tumor progression?

Designing functional experiments to assess SSEA-4's role in tumor progression requires multifaceted approaches:

• Genetic manipulation:

  • Knockdown studies: Use shRNA against ST3GAL2 (the SSEA-4 synthesizing enzyme) to reduce SSEA-4 expression, as demonstrated in DU145 cells where ST3GAL2 knockdown reduced SSEA-4+ cells from 21.5% to 4% .

  • Overexpression studies: Force expression of ST3GAL2 to increase SSEA-4 levels and assess phenotypic consequences.

• Cell adhesion assays:

  • Given that ST3GAL2 knockdown significantly decreased DU145 cell adhesion to various extracellular matrix components (collagen I, collagen IV, laminin, chondroitin sulfate) , design quantitative fluorometric cell adhesion assays to compare adhesion properties between manipulated and control cells.

• Migration and invasion assays:

  • Since SSEA-4+ cells form invadopodia-like migratory structures , use wound healing assays, transwell migration assays, or 3D invasion assays to assess migratory and invasive capabilities.

  • Study the colocalization of SSEA-4 with invasion-related markers (cortactin, pPI3K, pAkt, pSrc) in migratory structures using confocal microscopy .

• Tumorigenic potential assessment:

  • Xenotransplantation experiments with varying cell numbers (3,000 to 150,000) of SSEA-4+ and SSEA-4- populations to compare tumor-initiating capacity .

  • Compare SSEA-4+ cells with other putative cancer stem cell populations (e.g., CD44+ cells) for tumorigenic potential .

  • Analyze resulting tumors for heterogeneity, invasiveness, and metastatic capacity.

• Lineage tracing experiments:

  • Given the plasticity between SSEA-4+ and SSEA-4- states , design lineage tracing experiments to track the fate of SSEA-4+ cells in vivo.

• Signaling pathway analysis:

  • Investigate the signaling pathways activated in SSEA-4+ cells, focusing on those involved in EMT, stemness, and invasion (e.g., PI3K/Akt, Src pathways) .

  • Use specific inhibitors to determine which pathways are essential for SSEA-4-associated phenotypes.

What approaches can be used to study SSEA-4's role in cellular adhesion and EMT?

Studying SSEA-4's role in cellular adhesion and EMT requires specialized experimental approaches:

• Quantitative adhesion assays:

  • Fluorometric cell adhesion assays comparing control and ST3GAL2 knockdown cells on different ECM components (collagen I, collagen IV, laminin, chondroitin sulfate) .

  • Real-time cell analysis systems to monitor dynamic adhesion and spreading behaviors.

  • Atomic force microscopy to measure adhesion forces at the single-cell level.

• EMT marker profiling:

  • Comprehensive analysis of epithelial markers (CDH1/E-cadherin, ESRP1, GRHL2, CLDN7) and mesenchymal markers (CDH2/N-cadherin) in SSEA-4+ versus SSEA-4- populations .

  • Single-cell RNA sequencing to capture the heterogeneity and transitional states within SSEA-4+ populations.

  • Chromatin immunoprecipitation (ChIP) analysis to investigate whether EMT-associated transcription factors directly regulate SSEA-4 synthesis genes.

• Live cell imaging:

  • Track the formation of invadopodia-like migratory structures in real-time, correlating SSEA-4 localization with cellular behaviors .

  • Monitor the dynamic redistribution of SSEA-4 during cell migration using fluorescently tagged antibodies or SSEA-4 binding domains.

• Co-localization studies:

  • Investigate the co-localization of SSEA-4 with key adhesion molecules, EMT markers, and signaling components (pPI3K, pAkt, pSrc) in migratory structures using high-resolution confocal microscopy .

  • Proximity ligation assays to detect potential molecular interactions between SSEA-4 and adhesion/signaling proteins.

• 3D culture models:

  • Compare morphology, invasion patterns, and EMT marker expression in 3D organoid cultures derived from SSEA-4+ and SSEA-4- populations.

  • Use ECM-embedded spheroid invasion assays to assess collective versus single-cell invasion patterns.

• Manipulating glycosphingolipid metabolism:

  • Beyond ST3GAL2 knockdown , use specific inhibitors of glycosphingolipid synthesis or glycosidases to modulate SSEA-4 levels acutely.

  • Rescue experiments with exogenous SSEA-4 addition after synthesis inhibition to distinguish direct versus indirect effects.